HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serody, J. S. Articles by Frelinger, J. A. Search for Related Content PubMed PubMed Citation Articles by Serody, J. S. Articles by Frelinger, J. A.

T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery¹

Jonathan S. Serody^2,3,*,, Edward J. Collins2^,, Roland M. Tisch, Jennifer J. Kuhns and Jeffrey A. Frelinger

Departments of ^* Medicine, Microbiology and Immunology, and Biochemistry and Biophysics, University of North Carolina School of Medicine, and Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599

Previous work in both human and animal models has shown that CTL responses can be generated against proteins derived from tumors using either peptide-pulsed dendritic cells (DCs) or nucleic acids from the tumor transfected into autologous DCs. Despite the efficacy of this approach for vaccine therapy, many questions remain regarding whether the route of administration, the frequency of administration, or the type of Ag is critical to generating T cell responses to these Ags. We have investigated methods to enhance CTL responses to a peptide derived from the human proto-oncogene HER-2/neu using mice containing a chimeric HLA A2 and H2K^b allele. Changes in amino acids in the anchor positions of the peptide enhanced the binding of the peptide to HLA-A2 in vitro, but did not enhance the immunogenicity of the peptide in vivo. In contrast, when autologous DCs presented peptides, significant CTL activity was induced with the altered, but not the wild-type, peptide. We found that the route of administration affected the anatomic site and the time to onset of CTL activity, but did not impact on the magnitude of the response. To our surprise, we observed that weekly administration of peptide-pulsed DCs led to diminishing CTL activity after 6 wk of treatment. This was not found in animals injected with DCs every 3 wk for six treatments or in animals initially given DCs weekly and then injected weekly with peptide-pulsed C1R-A2 transfectants.

This article has been cited by other articles:

				C. Li, M. Hirsch, N. DiPrimio, A. Asokan, K. Goudy, R. Tisch, and R. J. Samulski Cytotoxic-T-Lymphocyte-Mediated Elimination of Target Cells Transduced with Engineered Adeno-Associated Virus Type 2 Vector In Vivo J. Virol., July 1, 2009; 83(13): 6817 - 6824. [Abstract] [Full Text] [PDF]

				C. Li, K. Goudy, M. Hirsch, A. Asokan, Y. Fan, J. Alexander, J. Sun, P. Monahan, D. Seiber, J. Sidney, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer PNAS, June 30, 2009; 106(26): 10770 - 10774. [Abstract] [Full Text] [PDF]

				R. S. Shabman, K. M. Rogers, and M. T. Heise Ross River Virus Envelope Glycans Contribute to Type I Interferon Production in Myeloid Dendritic Cells J. Virol., December 15, 2008; 82(24): 12374 - 12383. [Abstract] [Full Text] [PDF]

				C. Li, M. Hirsch, A. Asokan, B. Zeithaml, H. Ma, T. Kafri, and R. J. Samulski Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo J. Virol., July 15, 2007; 81(14): 7540 - 7547. [Abstract] [Full Text] [PDF]

				R. S. Shabman, T. E. Morrison, C. Moore, L. White, M. S. Suthar, L. Hueston, N. Rulli, B. Lidbury, J. P.-Y. Ting, S. Mahalingam, et al. Differential Induction of Type I Interferon Responses in Myeloid Dendritic Cells by Mosquito and Mammalian-Cell-Derived Alphaviruses J. Virol., January 1, 2007; 81(1): 237 - 247. [Abstract] [Full Text] [PDF]

				Y. Lou, G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo Cancer Res., September 15, 2004; 64(18): 6783 - 6790. [Abstract] [Full Text] [PDF]

				W. C. Bartholomae, F. H. Rininsland, J. C. Eisenberg, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann T Cell Immunity Induced by Live, Necrotic, and Apoptotic Tumor Cells J. Immunol., July 15, 2004; 173(2): 1012 - 1022. [Abstract] [Full Text] [PDF]

				L. A. O'Mara and P. M. Allen Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells J. Immunol., January 1, 2004; 172(1): 310 - 317. [Abstract] [Full Text] [PDF]

				D. W. Mullins, S. L. Sheasley, R. M. Ream, T. N.J. Bullock, Y.-X. Fu, and V. H. Engelhard Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control J. Exp. Med., October 6, 2003; 198(7): 1023 - 1034. [Abstract] [Full Text] [PDF]

				N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses J. Immunol., April 15, 2003; 170(8): 4242 - 4253. [Abstract] [Full Text] [PDF]

				C.-L. Lin, W.-F. Lo, T.-H. Lee, Y. Ren, S.-L. Hwang, Y.-F. Cheng, C.-L. Chen, Y.-S. Chang, S. P. Lee, A. B. Rickinson, et al. Immunization with Epstein-Barr Virus (EBV) Peptide-pulsed Dendritic Cells Induces Functional CD8+ T-Cell Immunity and May Lead to Tumor Regression in Patients with EBV-positive Nasopharyngeal Carcinoma Cancer Res., December 1, 2002; 62(23): 6952 - 6958. [Abstract] [Full Text] [PDF]

				A. Castilleja, D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, et al. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex J. Immunol., October 1, 2002; 169(7): 3545 - 3554. [Abstract] [Full Text] [PDF]

				A. Bacci, C. Montagnoli, K. Perruccio, S. Bozza, R. Gaziano, L. Pitzurra, A. Velardi, C. F. d'Ostiani, J. E. Cutler, and L. Romani Dendritic Cells Pulsed with Fungal RNA Induce Protective Immunity to Candida albicans in Hematopoietic Transplantation J. Immunol., March 15, 2002; 168(6): 2904 - 2913. [Abstract] [Full Text] [PDF]

				L. Fong, D. Brockstedt, C. Benike, L. Wu, and E. G. Engleman Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients J. Immunol., March 15, 2001; 166(6): 4254 - 4259. [Abstract] [Full Text] [PDF]

				B. Schuler-Thurner, D. Dieckmann, P. Keikavoussi, A. Bender, C. Maczek, H. Jonuleit, C. Roder, I. Haendle, W. Leisgang, R. Dunbar, et al. Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells J. Immunol., September 15, 2000; 165(6): 3492 - 3496. [Abstract] [Full Text] [PDF]